RxDoctor Payments Data

Timothy Daniel, MD

Endocrinology, Diabetes & Metabolism · Pearland, TXNPI 1770679573

Payments from drug & device makers

$78,093in general payments, 2019–2025

Across 583 payments — averaging $133.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$59K
  • Sanofi-aventis U.S. LLC$8K
  • Novo Nordisk$4K
  • Bayer$1K
  • Amarin Pharma, Inc.$834
  • Lilly USA, LLC$715
  • plus $5K from 39 others

What the payments were for

  • Consulting fees$53,37768%
  • Speaking & faculty fees$2,7003%
  • Travel & lodging$8,04710%
  • Food & beverage$13,80118%
  • Education$1680%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$78,093 in reported general payments places this provider in the 80th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.

See all endocrinology, diabetes & metabolism providers in Texas

Medicare billing

Part B allowed, 2024
$93,070
Medicare patients
226
Services billed
2,413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide1,014$1,331,463
MounjaroTirzepatide439$544,932
Soliqua 100-33Insulin Glargine/Lixisenatide356$390,770
JardianceEmpagliflozin396$347,896
TrulicityDulaglutide230$325,608
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog266$299,990
Trijardy XrEmpaglifloz/Linaglip/Metformin310$286,187
Tresiba Flextouch U-200Insulin Degludec188$209,112
FarxigaDapagliflozin Propanediol224$208,369
Humulin R U-500 KwikpenInsulin Regular, Human126$166,815
Synjardy XrEmpagliflozin/Metformin Hcl124$134,087
RybelsusSemaglutide98$124,595
Xigduo XrDapaglifloz Propaned/Metformin103$102,376
TradjentaLinagliptin117$83,849
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/729$56,527

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Novolog$3,712$1,509,5701,147 claims
Boehringer IngelheimJardiance, Trijardy Xr, Synjardy Xr, Tradjenta, Glyxambi$73$901,5411,009 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$715$878,397689 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$7,971$390,770356 claims
AstraZenecaFarxiga$435$208,369224 claims
MerckJanumet Xr, Januvia$164$43,46236 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.

Other endocrinology, diabetes & metabolism in Pearland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →